EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Circular RNA‐based neoantigen vaccine for hepatocellular carcinoma immunotherapy

Fei Wang, Guang Cai, Yingchao Wang, Qiuyu Zhuang, Zhixiong Cai, Yingying Li, Shaodong Gao, Fang Li, Cuilin Zhang, Bixing Zhao iD, Xiaolong Liu

MedComm · 2024-08 · 5 (8)

DOI: 10.1002/mco2.667 ↗

Kurz gefasst

Fachartikel in der Zeitschrift MedComm, online erschienen am 29.07.2024. Verfasst von Fei Wang und 10 weiteren Autor:innen. Beteiligte Einrichtung: The United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province Mengchao Hepatobiliary Hospital of Fujian Medical Univer…. Die Arbeit wurde bisher 67-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Science and Technology Projects of Fujian Province, National Natural Science Foundation of China, Fujian Provincial Health Technology Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

mRNA vaccines are regarded as a highly promising avenue for next‐generation cancer therapy. Nevertheless, the intricacy of production, inherent instability, and low expression persistence of linear mRNA significantly restrict their extensive utilization. Circular RNAs (circRNAs) offer a novel solution to these limitations due to their efficient protein expression ability, which can be rapidly generated in vitro without the need for extra modifications. Here, we present a novel neoantigen vaccine based on circRNA that induces a potent anti‐tumor immune response by expressing hepatocellular carcinoma‐specific tumor neoantigens. By cyclizing linearRNA molecules, we were able to enhance the stability of RNA vaccines and form highly stable circRNA molecules with the capacity for sustained protein expression. We confirmed that neoantigen‐encoded circRNA can promote dendritic cell (DC) activation and enhance DC‐induced T‐cell activation in vitro, thereby enhancing T‐cell killing of tumor cells. Encapsulating neoantigen‐encoded circRNA within lipid nanoparticles for in vivo expression has enabled the creation of a novel circRNA vaccine platform. This platform demonstrates superior tumor treatment and prevention in various murine tumor models, eliciting a robust T‐cell immune response. Our circRNA neoantigen vaccine offers new options and application prospects for neoantigen immunotherapy in solid tumors.

Schlagwörter

Stichwörter der Autor:innen

circRNAhepatocellular carcinomaimmunotherapyneoantigenvaccine

Autor:innen und Institutionen

  • The United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province Mengchao Hepatobiliary Hospital of Fujian Medical University Fuzhou P. R. China.
  • Fujian Provincial Clinical Research Center for Hepatobiliary and Pancreatic Tumors Fuzhou P. R. China.
  • Mengchao Med-X Center Fuzhou University Fuzhou P. R. China.
  • School of Basic Medical Sciences Fujian Medical University Fuzhou P. R. China.

ORCID-Profile: Bixing Zhao

Förderung

  • Science and Technology Projects of Fujian Province
  • National Natural Science Foundation of China
  • Fujian Provincial Health Technology Project

Zitieren

APA

Wang, F., Cai, G., Wang, Y., Zhuang, Q., Cai, Z., Li, Y., Gao, S., Li, F., Zhang, C., Zhao, B., & Liu, X. (2024). Circular RNA‐based neoantigen vaccine for hepatocellular carcinoma immunotherapy. MedComm, 5(8). https://doi.org/10.1002/mco2.667

Vancouver

Wang F, Cai G, Wang Y, Zhuang Q, Cai Z, Li Y, et al. Circular RNA‐based neoantigen vaccine for hepatocellular carcinoma immunotherapy. MedComm. 2024;5(8). doi:10.1002/mco2.667

BibTeX
@article{Wang2024,
  author = {Wang, Fei and Cai, Guang and Wang, Yingchao and Zhuang, Qiuyu and Cai, Zhixiong and Li, Yingying and Gao, Shaodong and Li, Fang and Zhang, Cuilin and Zhao, Bixing and Liu, Xiaolong},
  title = {Circular RNA‐based neoantigen vaccine for hepatocellular carcinoma immunotherapy},
  journal = {MedComm},
  year = {2024},
  volume = {5},
  number = {8},
  doi = {10.1002/mco2.667}
}
Kostenlos starten →